News

Study: Exposure history critical to design of universal flu vaccine


 

FROM SCIENCE TRANSLATIONAL MEDICINE

References

In a study with implications for the development of new influenza vaccine strategies, researchers discovered that – among patients who received the 2009 H1N1 influenza vaccine – individuals with low levels of H1N1-specific antibodies prior to vaccination produced a more broadly protective immune response against the influenza virus than patients with high levels of H1N1-specific antibodies prior to vaccination.

A research team led by Patrick C. Wilson, Ph.D., of the Knapp Center for Lupus and Immunology Research at the University of Chicago, studied the B cell response in patients who received the pandemic 2009 H1N1 vaccine 2 years in a row and had varied histories of influenza exposure. All patients were 18 years or older, healthy, and had not received the yearly influenza vaccine prior to participating in the study. The researchers compared the patients’ “vaccine-induced plasmablast response upon first vaccination with the pandemic H1N1 strain in 2009-2010” with the patients’ plasmablast response upon revaccination with this same strain in 2010-2011 or 2011-2012. Each of the 21 study participants provided the researchers with at least four H1N1-specific plasmablasts.

This highly magnified, digitally colorized transmission electron micrograph depicted numbers of virions from a novel flu H1N1 isolate. CDC/Cynthia Goldsmith

This highly magnified, digitally colorized transmission electron micrograph depicted numbers of virions from a novel flu H1N1 isolate.

The researchers “analyzed the immunoglobulin regions, strain specificity, and functional properties of the antibodies produced by this plasmablast population at the single-cell level across multiple years,” which allowed them to directly evaluate the effect of immune memory on the specificity of the current response to the virus.

Among the study’s findings was that “only individuals with low preexisting serological levels of pandemic H1N1 specific antibodies generated a broadly neutralizing plasmablast response directed toward the [hemagglutinin] stalk,” which is part of the hemagglutinin protein located on the surface of the influenza virus.

“[W]e demonstrate that the immune subdominance of the [hemagglutinin] stalk is a function of both the poor accessibility to the broadly protective epitopes and the inherent polyreactivity of the antibodies that can bind. We conclude that immunological memory profoundly shapes the viral epitopes targeted upon exposure with divergent influenza strains and determines the likelihood of generating a broadly protective response,” said Dr. Wilson and his coauthors. The authors reported no conflicts of interest.

Read the full study in Science Translational Medicine (doi: 10.1126/scitranslmed.aad0522).

klennon@frontlinemedcom.com

Recommended Reading

Shingles vaccine protection lasted 5-6 years in autoimmune disease patients
MDedge Family Medicine
HPV vaccinations not linked to CRPS and POTS in young women
MDedge Family Medicine
Progress toward measles elimination slows
MDedge Family Medicine
Staphylococcus aureus vaccine tolerable, immunogenic in preliminary study
MDedge Family Medicine
Improved supply chain, immunization rates key to global vaccination success
MDedge Family Medicine
Afghanistan still struggling with poliovirus
MDedge Family Medicine
Shingles vaccine protection lasted about 5 years in autoimmune disease patients
MDedge Family Medicine
ACR: Don’t give pneumococcal vaccine to CAPS, Behçet’s patients
MDedge Family Medicine
Prime-boost flu vaccination strategy effective in children
MDedge Family Medicine
ACIP weighs in on meningococcal B vaccines
MDedge Family Medicine